Giuseppe Ippolito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2910434/publications.pdf

Version: 2024-02-01

598 papers 28,117 citations

76 h-index 136 g-index

611 all docs

611 docs citations

611 times ranked

39580 citing authors

#	Article	IF	CITATIONS
1	Tâ€cell immune response after mRNA SARSâ€CoVâ€2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. British Journal of Haematology, 2022, 196, 548-558.	2.5	73
2	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	12.4	18
3	Coordinated cellular and humoral immune responses after twoâ€dose SARSâ€CoV2 mRNA vaccination in liver transplant recipients. Liver International, 2022, 42, 180-186.	3.9	36
4	Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. Neurology, 2022, 98, .	1.1	125
5	Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. International Journal of Infectious Diseases, 2022, 114, 268-272.	3.3	136
6	Analysis of HIV quasispecies and virological outcome of an HIV D+/R+ kidney–liver transplantation. Virology Journal, 2022, 19, 4.	3.4	1
7	The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals. IScience, 2022, 25, 103854.	4.1	3
8	Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. Cells, 2022, 11, 52.	4.1	11
9	Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. Scientific Reports, 2022, 12, 6687.	3.3	31
10	Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection. Nature Communications, 2022, 13, 2263.	12.8	6
11	Immune response in COVID-19: what is next?. Cell Death and Differentiation, 2022, 29, 1107-1122.	11.2	69
12	Vaccination for monkeypox prevention in persons with high-risk sexual behaviours to control on-going outbreak of monkeypox virus clade 3 International Journal of Infectious Diseases, 2022, 122, 569-571.	3.3	53
13	HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by inhibiting autophagy through E7-mediated degradation of AMBRA1. Autophagy, 2021, 17, 2842-2855.	9.1	25
14	COVIDâ€19 in people living with HIV: Clinical implications of dynamics of the immune response to SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 1796-1804.	5.0	38
15	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clinical Microbiology and Infection, 2021, 27, 286.e7-286.e13.	6.0	104
16	Zika virus NS2A inhibits interferon signaling by degradation of STAT1 and STAT2. Virulence, 2021, 12, 1580-1596.	4.4	21
17	Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing. International Journal of Environmental Research and Public Health, 2021, 18, 2174.	2.6	59
18	Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. Antibiotics, 2021, 10, 272.	3.7	60

#	Article	IF	CITATIONS
19	COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020. Biomolecules, 2021, 11, 425.	4.0	22
20	Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis. Cell Death and Disease, 2021, 12, 263.	6.3	89
21	Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. International Journal of Infectious Diseases, 2021, 113, S82-S87.	3.3	64
22	Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review. International Journal of Molecular Sciences, 2021, 22, 4526.	4.1	48
23	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell, 2021, 184, 1821-1835.e16.	28.9	180
24	Saliva Is a Valid Alternative to Nasopharyngeal Swab in Chemiluminescence-Based Assay for Detection of SARS-CoV-2 Antigen. Journal of Clinical Medicine, 2021, 10, 1471.	2.4	19
25	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. Journal of Infection, 2021, 82, 58-66.	3.3	44
26	SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses, 2021, 13, 655.	3.3	48
27	High Levels of TRIM5α Are Associated with Xenophagy in HIV-1-Infected Long-Term Nonprogressors. Cells, 2021, 10, 1207.	4.1	6
28	Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. Scientific Reports, 2021, 11, 11334.	3.3	2
29	Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection. Antiviral Research, 2021, 190, 105064.	4.1	37
30	Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. International Journal of Infectious Diseases, 2021, 107, 247-250.	3.3	38
31	Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. Journal of Translational Medicine, 2021, 19, 272.	4.4	19
32	Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. Microorganisms, 2021, 9, 1315.	3.6	54
33	Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. Vaccines, 2021, 9, 615.	4.4	15
34	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death and Differentiation, 2021, 28, 3297-3315.	11.2	31
35	Outcomes and Timing of Bedside Percutaneous Tracheostomy of COVID-19 Patients over a Year in the Intensive Care Unit. Journal of Clinical Medicine, 2021, 10, 3335.	2.4	7
36	Benefits of Steroid Therapy in COVID-19 Patients with Different PaO2/FiO2 Ratio at Admission. Journal of Clinical Medicine, 2021, 10, 3236.	2.4	4

#	Article	IF	CITATIONS
37	Rationale and Criteria for a COVID-19 Model Framework. Viruses, 2021, 13, 1309.	3.3	3
38	Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy. BMC Infectious Diseases, 2021, 21, 667.	2.9	6
39	Looking for pathways related to COVID-19: confirmation of pathogenic mechanisms by SARS-CoV-2–host interactome. Cell Death and Disease, 2021, 12, 788.	6.3	13
40	Diagnosis of Chikungunya Virus in Febrile Patients From a Malaria Holoendemic Area. International Journal of Infectious Diseases, 2021, 109, 247-252.	3.3	9
41	Expansion of Myeloid Derived Suppressor Cells Contributes to Platelet Activation by L-Arginine Deprivation during SARS-CoV-2 Infection. Cells, 2021, 10, 2111.	4.1	36
42	Neuropathology and Inflammatory Cell Characterization in 10 Autoptic COVID-19 Brains. Cells, 2021, 10, 2262.	4.1	37
43	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine, 2021, 27, 1752-1760.	30.7	353
44	ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. Frontiers in Immunology, 2021, 12, 740249.	4.8	70
45	INMI1 Zika Virus NS4B Antagonizes the Interferon Signaling by Suppressing STAT1 Phosphorylation. Viruses, 2021, 13, 2448.	3.3	17
46	Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021. Frontiers in Medicine, 2021, 8, 815870.	2.6	8
47	Multi-omics approach to COVID-19: a domain-based literature review. Journal of Translational Medicine, 2021, 19, 501.	4.4	18
48	Ebola: Basic and Social Science, Public Health, and Policy at the Crossroads. Journal of Infectious Diseases, 2020, 221, 687-689.	4.0	0
49	Full-length genome sequence of a dengue serotype 1 virus isolate from a traveler returning from Democratic Republic of Congo to Italy, July 2019. International Journal of Infectious Diseases, 2020, 92, 46-48.	3.3	10
50	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 681-689.	3.0	8
51	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. Emerging Infectious Diseases, 2020, 26, 2709-2712.	4.3	133
52	SARS-CoV-2 Phylogenetic Analysis, Lazio Region, Italy, February–March 2020. Emerging Infectious Diseases, 2020, 26, 1842-1845.	4.3	33
53	Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress, 2020, 4, 66-75.	3.2	271
54	Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. International Journal of Infectious Diseases, 2020, 98, 454-459.	3.3	49

#	Article	IF	Citations
55	Virus-Negative Myopericarditis in Human Coronavirus Infection. Circulation: Heart Failure, 2020, 13, CIRCHEARTFAILURE120007636.	3.9	20
56	SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection. Annals of Internal Medicine, 2020, 173, 242-243.	3.9	266
57	Spatial modes for transmission of chikungunya virus during a large chikungunya outbreak in Italy: a modeling analysis. BMC Medicine, 2020, 18, 226.	5.5	17
58	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death and Disease, 2020, 11, 921.	6.3	96
59	Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay. Viruses, 2020, 12, 1184.	3.3	18
60	COVID-19 and tuberculosisâ€"threats and opportunities. International Journal of Tuberculosis and Lung Disease, 2020, 24, 757-760.	1.2	45
61	Chikungunya Outbreak in the Republic of the Congo, 2019—Epidemiological, Virological and Entomological Findings of a South-North Multidisciplinary Taskforce Investigation. Viruses, 2020, 12, 1020.	3.3	15
62	Immune responses during COVID-19 infection. OncoImmunology, 2020, 9, 1807836.	4.6	103
63	Compartmentalized Replication of SARS-Cov-2 in Upper vs. Lower Respiratory Tract Assessed by Whole Genome Quasispecies Analysis. Microorganisms, 2020, 8, 1302.	3.6	40
64	Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. Journal of Infectious Diseases, 2020, 222, 1807-1815.	4.0	167
65	Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics. Open Forum Infectious Diseases, 2020, 7, ofaa403.	0.9	17
66	Lessons from the COVID-19 Pandemic—Unique Opportunities for Unifying, Revamping and Reshaping Epidemic Preparedness of Europe's Public Health Systems. International Journal of Infectious Diseases, 2020, 101, 361-366.	3.3	8
67	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies. International Journal of Infectious Diseases, 2020, 96, 431-439.	3.3	43
68	Implementing a combined infection prevention and control with antimicrobial stewardship joint program to prevent caesarean section surgical site infections and antimicrobial resistance: a Tanzanian tertiary hospital experience. Antimicrobial Resistance and Infection Control, 2020, 9, 69.	4.1	18
69	An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 2272-2275.	5.8	91
70	Origin of HAV strains responsible for 2016–2017 outbreak among MSM: Viral phylodynamics in Lazio region. PLoS ONE, 2020, 15, e0234010.	2.5	5
71	COVIDâ€19 and reninâ€angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ―ls there any scientific evidence for controversy?. Journal of Internal Medicine, 2020, 288, 410-421.	6.0	38
72	Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death and Differentiation, 2020, 27, 3196-3207.	11,2	196

#	Article	IF	Citations
73	COVID-19: viral–host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. Journal of Translational Medicine, 2020, 18, 233.	4.4	80
74	National Institute for the Infectious Diseases "L. Spallanzani―IRCCS. Recommendations for COVID-19 Clinical Management. Gastroenterology Insights, 2020, 12, 8543.	1.2	139
75	Mass gathering events and reducing further global spread of COVID-19: a political and public health dilemma. Lancet, The, 2020, 395, 1096-1099.	13.7	275
76	Host-directed therapies and holistic care for tuberculosis. Lancet Respiratory Medicine, the, 2020, 8, 337-340.	10.7	12
77	Commemorating World TB Day 2020: "IT'S TIME―— It's time to End the Global TB Epidemic. Interna Journal of Infectious Diseases, 2020, 92, S1-S4.	atjonal	6
78	COVID-19 infection: the perspectives on immune responses. Cell Death and Differentiation, 2020, 27, 1451-1454.	11.2	1,217
79	Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test. Journal of Clinical Virology, 2020, 129, 104539.	3.1	82
80	Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nature Communications, 2020, 11, 3410.	12.8	328
81	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. European Respiratory Journal, 2020, 56, 2001727.	6.7	89
82	2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. International Journal of Infectious Diseases, 2020, 93, 192-197.	3.3	145
83	Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future. International Journal of Infectious Diseases, 2020, 93, 233-236.	3.3	150
84	Toning down the 2019-nCoV media hypeâ€"and restoring hope. Lancet Respiratory Medicine,the, 2020, 8, 230-231.	10.7	51
85	The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 2020, 91, 264-266.	3.3	2,658
86	Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy. Clinical Microbiology and Infection, 2020, 26, 954-956.	6.0	91
87	Usefulness of bronchoalveolar lavage in the management of patients presenting with lung infiltrates and suspect COVID-19-associated pneumonia: A case report. International Journal of Infectious Diseases, 2020, 97, 174-176.	3.3	26
88	Europe's public-health systems gear up for future epidemics. Nature, 2020, 586, 674-674.	27.8	1
89	COVID-19 diseaseâ€"Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study. PLoS ONE, 2020, 15, e0244129.	2.5	35
90	Negative Regulation of Mitochondrial Antiviral Signaling Protein–Mediated Antiviral Signaling by the Mitochondrial Protein LRPPRC During Hepatitis C Virus Infection. Hepatology, 2019, 69, 34-50.	7.3	36

#	Article	IF	Citations
91	<p>Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in bla_{KPC-3}-harboring Klebsiella pneumoniae</p> . Infection and Drug Resistance, 2019, Volume 12, 1935-1940.	2.7	22
92	Household transmission and disease transmissibility of a large HAV outbreak in Lazio, Italy, 2016–2017. Epidemics, 2019, 29, 100351.	3.0	8
93	High-income countries and latent tuberculosis infection screening for migrants – Authors' reply. Lancet Infectious Diseases, The, 2019, 19, 691-692.	9.1	2
94	Chikungunya. Infectious Disease Clinics of North America, 2019, 33, 1003-1025.	5.1	101
95	Geographical Variability Affects CCHFV Detection by RT–PCR: A Tool for In-Silico Evaluation of Molecular Assays. Viruses, 2019, 11, 953.	3.3	10
96	Pulmonary Involvement during the Ebola Virus Disease. Viruses, 2019, 11, 780.	3.3	6
97	Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. Lancet Infectious Diseases, The, 2019, 19, e444-e451.	9.1	14
98	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. Journal of Antimicrobial Chemotherapy, 2019, 74, 3295-3304.	3.0	14
99	VÎ 2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity. Microorganisms, 2019, 7, 350.	3.6	9
100	Effectiveness of dolutegravirâ€based regimens as either firstâ€line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	3.0	46
101	Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014–2016 Outbreak in West Africa. Viruses, 2019, 11, 373.	3.3	28
102	Latent TB Infection (LTBI) $\hat{a}\in$ Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground. International Journal of Infectious Diseases, 2019, 80, S58-S61.	3.3	30
103	Recent advances in the development and evaluation of molecular diagnostics for Ebola virus disease. Expert Review of Molecular Diagnostics, 2019, 19, 325-340.	3.1	12
104	Unawareness of HCV serostatus among persons newly diagnosed with HIV. Journal of Infection and Public Health, 2019, 12, 733-737.	4.1	2
105	NK Cells Accumulate in Infected Tissues and Contribute to Pathogenicity of Ebola Virus in Mice. Journal of Virology, 2019, 93, .	3.4	13
106	Orthopoxvirus Seroprevalence in Cats and Veterinary Personnel in North-Eastern Italy in 2011. Viruses, 2019, 11, 101.	3.3	4
107	New filovirus disease classification and nomenclature. Nature Reviews Microbiology, 2019, 17, 261-263.	28.6	84
108	Tropism of the Chikungunya Virus. Viruses, 2019, 11, 175.	3.3	85

#	Article	IF	CITATIONS
109	Tuberculin skin test – Outdated or still useful for Latent TB infection screening?. International Journal of Infectious Diseases, 2019, 80, S20-S22.	3.3	26
110	Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study. Journal of Infectious Diseases, 2019, 220, 195-202.	4.0	38
111	Latent tuberculosis infection: diagnostic tests and when to treat. Lancet Infectious Diseases, The, 2019, 19, 231-233.	9.1	15
112	World Tuberculosis Day March 24th 2019 Theme: "lt's TIME―â€" International Journal of Infectious Diseases Tuberculosis Theme Series. International Journal of Infectious Diseases, 2019, 80, S1-S5.	3.3	3
113	Improving treatment outcomes for MDR-TB â€" Novel host-directed therapies and personalised medicine of the future. International Journal of Infectious Diseases, 2019, 80, S62-S67.	3.3	29
114	Viral Hemorrhagic Fevers Other than Ebola and Lassa. Infectious Disease Clinics of North America, 2019, 33, 977-1002.	5.1	32
115	Ebola Virus Disease. Infectious Disease Clinics of North America, 2019, 33, 953-976.	5.1	36
116	Viral Hepatitis. Infectious Disease Clinics of North America, 2019, 33, 1045-1062.	5.1	93
117	Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 190-200.	1.5	6
118	Monkeypox â€" Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. International Journal of Infectious Diseases, 2019, 78, 78-84.	3.3	133
119	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaA ve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. HIV Medicine, 2019, 20, 99-109.	2.2	19
120	Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. International Journal of Antimicrobial Agents, 2019, 53, 559-563.	2.5	14
121	Transportation capacity for patients with highly infectious diseases in Europe: a survey in 16 nations. Clinical Microbiology and Infection, 2019, 21, e1-e5.	6.0	11
122	Unexpected human cases of cutaneous anthrax in Latium region, Italy, August 2017: integrated human–animal investigation of epidemiological, clinical, microbiological and ecological factors. Eurosurveillance, 2019, 24, .	7.0	5
123	Expanding Usutu virus circulation in Italy: detection in the Lazio region, central Italy, 2017 to 2018. Eurosurveillance, 2019, 24, .	7.0	29
124	Laboratory management of Crimean-Congo haemorrhagic fever virus infections: perspectives from two European networks. Eurosurveillance, 2019, 24, .	7.0	27
125	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting) Tj ETQq1 1 0.784 24. S71-S82.	1314 rgBT 6.0	/Overlock 1 157
126	Occupational transmission of an Orthopoxvirus infection during an outbreak in a colony of <i>Macaca tonkeana</i> in Lazio Region, Italy, 2015. Zoonoses and Public Health, 2018, 65, 578-583.	2.2	7

#	Article	IF	CITATIONS
127	Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. Clinical Infectious Diseases, 2018, 66, 36-44.	5.8	12
128	Discharge Criteria for Patient With Lassa Fever Infection. Clinical Infectious Diseases, 2018, 66, 638-638.	5.8	1
129	EBOLA Ag K-SeT rapid test: field evaluation in Sierra Leone. Clinical Microbiology and Infection, 2018, 24, 653-657.	6.0	10
130	Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis C?. Clinical Microbiology and Infection, 2018, 24, 328-331.	6.0	5
131	Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 — "Wanted: Leaders for a TB-Free World. You can make history. End TB― International Journal of Infectious Diseases, 2018, 68, 122-124.	3.3	9
132	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting) Tj ETQq0 0 0 rgE Clinical Microbiology and Infection, 2018, 24, S83-S94.	BT/Overlo	ck 10 Tf 50
133	Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infectious Diseases, The, 2018, 18, e183-e198.	9.1	281
134	Reply to Reisler et al. Clinical Infectious Diseases, 2018, 66, 1480-1481.	5.8	0
135	Evaluation of a rapid and sensitive RT-qPCR assay for the detection of Ebola Virus. Journal of Virological Methods, 2018, 252, 70-74.	2.1	21
136	Whole Genome Characterization of Orthopoxvirus (OPV) Abatino, a Zoonotic Virus Representing a Putative Novel Clade of Old World Orthopoxviruses. Viruses, 2018, 10, 546.	3.3	17
137	Local transmission of chikungunya in Rome and the Lazio region, Italy. PLoS ONE, 2018, 13, e0208896.	2.5	33
138	Highly infectious diseases in the Mediterranean Sea area: Inventory of isolation capabilities and recommendations for appropriate isolation. New Microbes and New Infections, 2018, 26, S65-S73.	1.6	4
139	The Surveillance of Chikungunya Virus in a Temperate Climate: Challenges and Possible Solutions from the Experience of Lazio Region, Italy. Viruses, 2018, 10, 501.	3.3	17
140	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 3460-3470.	3.0	8
141	Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection. Scientific Reports, 2018, 8, 15626.	3.3	23
142	Molecular Characterization of Autochthonous Chikungunya Cluster in Latium Region, Italy. Emerging Infectious Diseases, 2018, 24, 178-180.	4.3	17
143	Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Review of Anti-Infective Therapy, 2018, 16, 501-512.	4.4	53
144	ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC. Mediators of Inflammation, 2018, 2018, 1-6.	3.0	28

#	Article	IF	Citations
145	A retrospective evaluation of bites at risk of rabies transmission across 7 years: The need to improve surveillance and reporting systems for rabies elimination. PLoS ONE, 2018, 13, e0197996.	2.5	9
146	The European Virus Archive goes global: A growing resource for research. Antiviral Research, 2018, 158, 127-134.	4.1	30
147	Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa. Intensive Care Medicine, 2018, 44, 1266-1275.	8.2	16
148	Global epidemiology of viral hepatitis and national needs for complete control. Expert Review of Anti-Infective Therapy, 2018, 16, 625-639.	4.4	22
149	Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infectious Diseases, 2018, 18, 223.	2.9	19
150	HIV rapid testing in community and outreach sites: results of a nationwide demonstration project in Italy. BMC Public Health, 2018, 18, 748.	2.9	16
151	Serological evaluation for Chagas disease in migrants from Latin American countries resident in Rome, Italy. BMC Infectious Diseases, 2018, 18, 212.	2.9	16
152	Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection. Tuberculosis, 2018, 111, 147-153.	1.9	42
153	Prolonged detection of dengue virus RNA in the semen of a man returning from Thailand to Italy, January 2018. Eurosurveillance, 2018, 23, .	7.0	25
154	Status, quality and specific needs of Ebola virus diagnostic capacity and capability in laboratories of the two European preparedness laboratory networks EMERGE and EVD-LabNet. Eurosurveillance, 2018, 23, .	7.0	9
155	Persistence of ZIKV-RNA in the cellular fraction of semen is accompanied by a surrogate-marker of viral replication. Diagnostic implications for sexual transmission. New Microbiologica, 2018, 41, 30-33.	0.1	7
156	Role of autophagy in <scp>HIV</scp> infection and pathogenesis. Journal of Internal Medicine, 2017, 281, 422-432.	6.0	54
157	Human Endometrial Stromal Cells Are Highly Permissive To Productive Infection by Zika Virus. Scientific Reports, 2017, 7, 44286.	3.3	50
158	The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. International Journal of Infectious Diseases, 2017, 56, 45-53.	3.3	37
159	Ebola virus infection induces autoimmunity against dsDNA and HSP60. Scientific Reports, 2017, 7, 42147.	3.3	14
160	Declining unawareness of HCVâ€infection parallel to declining prevalence in Southern Italy. Journal of Medical Virology, 2017, 89, 1691-1692.	5.0	8
161	Evaluation of the inactivation effect of Triton X-100 on Ebola virus infectivity. Journal of Clinical Virology, 2017, 86, 27-30.	3.1	27
162	Enhancing preparedness for tackling new epidemic threats. Lancet Respiratory Medicine, the, 2017, 5, 606-608.	10.7	8

#	Article	IF	Citations
163	Preface $\hat{a} \in ``Emerging Viruses: From Early Detection to Intervention. Advances in Experimental Medicine and Biology, 2017, 972, 1-5.$	1.6	3
164	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clinical Microbiology and Infection, 2017, 23, 267.e1-267.e4.	6.0	11
165	Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Research, 2017, 140, 13-17.	4.1	88
166	Human Zika infection induces a reduction of IFN- \hat{l}^3 producing CD4 T-cells and a parallel expansion of effector VÎ'2 T-cells. Scientific Reports, 2017, 7, 6313.	3.3	35
167	A Tâ€cell diagnostic test for cystic echinococcosis based on Antigen B peptides. Parasite Immunology, 2017, 39, e12499.	1.5	13
168	Travel-Associated Zika Virus Disease. Annals of Internal Medicine, 2017, 166, 913.	3.9	0
169	Reliability and validity of using telephone calls for post-discharge surveillance of surgical site infection following caesarean section at a tertiary hospital in Tanzania. Antimicrobial Resistance and Infection Control, 2017, 6, 43.	4.1	39
170	Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis, 2017, 106, 38-43.	1.9	89
171	Impact of infectious disease epidemics on tuberculosis diagnostic, management, and prevention services: experiences and lessons from the 2014–2015 Ebola virus disease outbreak in West Africa. International Journal of Infectious Diseases, 2017, 56, 101-104.	3.3	38
172	The contribution of the European high containment laboratories during the 2014–2015 Ebola Virus Disease emergency. Clinical Microbiology and Infection, 2017, 23, 58-60.	6.0	3
173	Full-Length Genome Sequence of a Chikungunya Virus Isolate from the 2017 Autochthonous Outbreak, Lazio Region, Italy. Genome Announcements, 2017, 5, .	0.8	10
174	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators of Inflammation, 2017, 2017, 1-15.	3.0	93
175	Enterovirus D68–Associated Acute Flaccid Myelitis in Immunocompromised Woman, Italy. Emerging Infectious Diseases, 2017, 23, 1690-1693.	4.3	26
176	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. PLoS ONE, 2017, 12, e0189425.	2.5	6
177	Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease: a case report. BMC Infectious Diseases, 2017, 17, 597.	2.9	4
178	Measles Cases during Ebola Outbreak, West Africa, 2013–2106. Emerging Infectious Diseases, 2017, 23, 1035-1037.	4.3	21
179	Persistent detection of dengue virus RNA in vaginal secretion of a woman returning from Sri Lanka to Italy, April 2017. Eurosurveillance, 2017, 22, .	7.0	16
180	Different features of \hat{V} T and NK cells in fatal and non-fatal human Ebola infections. PLoS Neglected Tropical Diseases, 2017, 11, e0005645.	3.0	46

#	Article	IF	CITATIONS
181	QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Neglected Tropical Diseases, 2017, 11, e0006034.	3.0	71
182	A large ongoing outbreak of hepatitis A predominantly affecting young males in Lazio, Italy; August 2016 - March 2017. PLoS ONE, 2017, 12, e0185428.	2.5	37
183	Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient. PLoS Pathogens, 2017, 13, e1006065.	4.7	14
184	An outbreak of chickenpox in an asylum seeker centre in Italy: outbreak investigation and validity of reported chickenpox history, December 2015–May 2016. Eurosurveillance, 2017, 22, .	7.0	17
185	Hepatitis C virus relies on lipoproteins for its life cycle. World Journal of Gastroenterology, 2016, 22, 1953.	3.3	47
186	A New Era in the Control of Tuberculosis. Gastroenterology Insights, 2016, 8, 6644.	1.2	0
187	Clinical, Virologic, and Epidemiologic Characteristics of Dengue Outbreak, Dar es Salaam, Tanzania, 2014. Emerging Infectious Diseases, 2016, 22, 895-899.	4.3	39
188	Zika Virus Infection in the Central Nervous System and Female Genital Tract. Emerging Infectious Diseases, 2016, 22, 2228-2230.	4.3	59
189	Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. Eurosurveillance, 2016, 21, .	7.0	236
190	Diagnosis of Zika virus infection in pregnant women travelling to or residing in endemic areas. Lancet Infectious Diseases, The, 2016, 16, 771-772.	9.1	4
191	How many people are living with undiagnosed HIV infection? An estimate for Italy, based on surveillance data. Aids, 2016, 30, 1131-1136.	2.2	25
192	Modulation of interferon-gamma response to QuantiFERON-TB-plus detected by enzyme-linked immunosorbent assay in patients with active and latent tuberculosis infection. International Journal of Mycobacteriology, 2016, 5, S143-S144.	0.6	7
193	Temporal trend of hospital discharge for non alcoholic cirrhosis in Lazio Region, Italy 2000–2014. European Journal of Internal Medicine, 2016, 33, e16-e17.	2.2	0
194	Sampling Surfaces for Ebola Virus Persistence After Cleaning Procedures in High-Level Isolation Settings: The Experience With 2 Patients at the Lazzaro Spallanzani National Institute for Infectious Diseases. Infection Control and Hospital Epidemiology, 2016, 37, 723-725.	1.8	4
195	Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Science Translational Medicine, 2016, 8, 329ra33.	12.4	78
196	The Middle East Respiratory Syndrome Coronavirus – A Continuing Risk to Global Health Security. Advances in Experimental Medicine and Biology, 2016, 972, 49-60.	1.6	30
197	Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit. International Journal of Mycobacteriology, 2016, 5, S25-S26.	0.6	12
198	Modulation of CD4 and CD8 response to QuantiFERON-TB Plus in patients with active tuberculosis and latent tuberculosis infection followed over time during treatment. International Journal of Mycobacteriology, 2016, 5, S141-S142.	0.6	2

#	Article	IF	CITATIONS
199	Post-caesarean section surgical site infections at a Tanzanian tertiary hospital: a prospective observational study. Journal of Hospital Infection, 2016, 93, 355-359.	2.9	40
200	Zika virus in salivaâ€"New challenges for prevention of human to human transmission. European Journal of Internal Medicine, 2016, 33, e20-e21.	2.2	10
201	Transitory ventricular tachycardia associated with influenza A infection of cardiac conduction tissue. Infection, 2016, 44, 353-356.	4.7	9
202	Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection. Cell Death and Disease, 2016, 7, e2164-e2164.	6.3	51
203	The diabetes-tuberculosis co-epidemic: the role of international migration. International Journal of Tuberculosis and Lung Disease, 2016, 20, 771-777.	1.2	5
204	Non-randomised Ebola trialsâ€"lessons for optimal outbreak research. Lancet Infectious Diseases, The, 2016, 16, 407-408.	9.1	5
205	First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. Journal of Infection, 2016, 73, 588-597.	3.3	101
206	Hepatitis C: global epidemiology and strategies for control. Clinical Microbiology and Infection, 2016, 22, 833-838.	6.0	137
207	Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals. Clinical Microbiology and Infection, 2016, 22, 824-825.	6.0	0
208	Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015. Journal of Infectious Diseases, 2016, 214, S250-S257.	4.0	32
209	Enabling Rapid Response to the 2014–2016 Ebola Epidemic: The Experience and the Results of the National Institute for Infectious Diseases Lazzaro Spallanzani. Advances in Experimental Medicine and Biology, 2016, 972, 103-122.	1.6	2
210	Three cases of Zika virus imported in Italy: need for a clinical awareness and evidence-based knowledge. BMC Infectious Diseases, 2016, 16, 669.	2.9	7
211	Web-Based HIV Testing in Abruzzo, Italy: Analysis of 15-Month Activity Results. AIDS Patient Care and STDs, 2016, 30, 471-475.	2.5	10
212	Temporary neurocognitive impairment with Ebola virus. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1386-1387.	1.9	11
213	Prioritization of High Consequence Viruses to Improve European Laboratory Preparedness for Cross-Border Health Threats. Advances in Experimental Medicine and Biology, 2016, 972, 123-129.	1.6	2
214	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 2663-2669.	3.0	10
215	Lessons learnt from TB screening in closed immigration centres in Italy. International Health, 2016, 8, 324-329.	2.0	13
216	Taking forward a â€~One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential. International Journal of Infectious Diseases, 2016, 47, 5-9.	3.3	81

#	Article	IF	Citations
217	Steroid use and clinical sequelae in two survivors of EVD. Lancet Infectious Diseases, The, 2016, 16, 638.	9.1	2
218	Liver transplant recipients and prioritization of antiâ€ <scp>HCV</scp> therapy: an Italian cohort analysis. Liver International, 2016, 36, 410-417.	3.9	4
219	Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?. Expert Review of Anti-Infective Therapy, 2016, 14, 19-27.	4.4	1
220	Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infectious Diseases, The, 2016, 16, e47-e63.	9.1	265
221	Clinical Management of Ebola Virus Disease in the United States and Europe. New England Journal of Medicine, 2016, 374, 636-646.	27.0	316
222	Rapid Spread of Zika Virus in The Americas - Implications for Public Health Preparedness for Mass Gatherings at the 2016 Brazil Olympic Games. International Journal of Infectious Diseases, 2016, 44, 11-15.	3.3	306
223	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clinical Microbiology and Infection, 2016, 22, 288.e1-288.e8.	6.0	33
224	Histological and proteomic profile of diabetic versus non-diabetic dilated cardiomyopathy. International Journal of Cardiology, 2016, 203, 282-289.	1.7	21
225	A 2009 cross-sectional survey of procedures for post-mortem management of highly infectious disease patients in 48 isolation facilities in 16 countries: data from EuroNHID. Infection, 2016, 44, 57-64.	4.7	12
226	INMI/Emergency NGO Italian Laboratory Established In Sierra Leone during Ebola Virus Disease Outbreak in West Africa. Clinical Microbiology and Infectious Diseases, 2016, 1, .	0.1	5
227	Induction of autophagy promotes the growth of early preneoplastic rat liver nodules. Oncotarget, 2016, 7, 5788-5799.	1.8	32
228	Surgical site infection after caesarean section: space for post-discharge surveillance improvements and reliable comparisons. New Microbiologica, 2016, 39, 134-8.	0.1	10
229	Short-term economic impact of the Zika virus outbreak. New Microbiologica, 2016, 39, 287-289.	0.1	30
230	Adopting a Global Safety Standard for the Prevention of Ebola Needle-Stick Exposures. Infection Control and Hospital Epidemiology, 2015, 36, 745-746.	1.8	2
231	Criteria for discharge of patients with Ebola virus diseases in high-income countries. The Lancet Global Health, 2015, 3, e739-e740.	6.3	11
232	Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infectious Diseases, 2015, 15, 432.	2.9	36
233	Molecular Signature of the Ebola Virus Associated with the Fishermen Community Outbreak in Aberdeen, Sierra Leone, in February 2015. Genome Announcements, 2015, 3, .	0.8	3
234	Tuberculosis Transmission from Healthcare Workers to Patients and Co-workers: A Systematic Literature Review and Meta-Analysis. PLoS ONE, 2015, 10, e0121639.	2.5	19

#	Article	IF	Citations
235	The chronology of the international response to Ebola in Western Africa: lights and shadows in a frame of conflicting position and figures. Gastroenterology Insights, 2015, 7, 5957.	1.2	8
236	Incidence of Carbapenem-Resistant Gram Negatives in Italian Transplant Recipients: A Nationwide Surveillance Study. PLoS ONE, 2015, 10, e0123706.	2.5	68
237	Radiographic imaging in Ebola Virus Disease: protocol to acquire chest radiographs. European Radiology, 2015, 25, 3368-3371.	4.5	5
238	Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?. Lancet Infectious Diseases, The, 2015, 15, 738-745.	9.1	42
239	Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death and Differentiation, 2015, 22, 1250-1259.	11.2	127
240	Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14331-14336.	7.1	58
241	Epidemiology of HEV in the Mediterranean basin: 10-year prevalence in Italy. BMJ Open, 2015, 5, e007110.	1.9	35
242	Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: A case study using ultra deep pyrosequencing. Journal of Clinical Virology, 2015, 66, 38-43.	3.1	13
243	A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis, 2015, 95, 713-721.	1.9	35
244	Molecular Characterization of the First Ebola Virus Isolated in Italy, from a Health Care Worker Repatriated from Sierra Leone. Genome Announcements, 2015, 3, .	0.8	10
245	Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates: Table 1 Clinical Infectious Diseases, 2015, 61, 1432-1438.	5.8	38
246	Ebola: missed opportunities for Europe–Africa research. Lancet Infectious Diseases, The, 2015, 15, 1254-1255.	9.1	13
247	Europe needs Ebola outbreak consortium. Nature, 2015, 523, 35-35.	27.8	4
248	Towards host-directed therapies for tuberculosis. Nature Reviews Drug Discovery, 2015, 14, 511-512.	46.4	110
249	Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa. Nature, 2015, 524, 97-101.	27.8	272
250	Disinfection of personal protective equipment for management of Ebola patients. American Journal of Infection Control, 2015, 43, 1375-1376.	2.3	4
251	Considerations regarding safe transport and transfer for Ebola patients in western countries. Intensive Care Medicine, 2015, 41, 1175-1176.	8.2	4
252	The added value of long-lasting preparedness for the management of a patient with Ebola. European Journal of Internal Medicine, 2015, 26, 451-452.	2.2	7

#	Article	IF	CITATIONS
253	Hospital preparedness for knowledge-based response to Ebola and other emerging infectious diseases: A continuous challenge. European Journal of Internal Medicine, 2015, 26, 454-455.	2.2	4
254	Autophagy regulates hepatocyte identity and epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions promoting Snail degradation. Cell Death and Disease, 2015, 6, e1880-e1880.	6.3	96
255	Is hepatitis C virus eradication around the corner only 25 years after its discovery?. International Journal of Antimicrobial Agents, 2015, 45, 111-112.	2.5	19
256	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non–AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. Journal of Infectious Diseases, 2015, 211, 178-186.	4.0	146
257	Blood kinetics of Ebola virus in survivors and nonsurvivors. Journal of Clinical Investigation, 2015, 125, 4692-4698.	8.2	82
258	Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. Journal of Clinical Investigation, 2015, 125, 4421-4428.	8.2	102
259	Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts. PLoS Neglected Tropical Diseases, 2015, 9, e0004209.	3.0	27
260	Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro. PLoS ONE, 2015, 10, e0116816.	2.5	15
261	Ebola in West Africa: who pays for what in the outbreak?. New Microbiologica, 2015, 38, 1-3.	0.1	20
262	Isolation Facilities for Highly Infectious Diseases in Europe – A Cross-Sectional Analysis in 16 Countries. PLoS ONE, 2014, 9, e100401.	2.5	22
263	Benefits of a European Project on Diagnostics of Highly Pathogenic Agents and Assessment of Potential ââ,¬Å"Dual Useââ,¬Â•lssues. Frontiers in Public Health, 2014, 2, 199.	2.7	7
264	lgG Against Dengue Virus in Healthy Blood Donors, Zanzibar, Tanzania. Emerging Infectious Diseases, 2014, 20, 465-8.	4.3	33
265	Biopsy-proven autoimmune myocarditis in HIV-associated dilated cardiomyopathy. BMC Infectious Diseases, 2014, 14, 729.	2.9	12
266	Ebola and travel – Management of imported cases. Travel Medicine and Infectious Disease, 2014, 12, 561-562.	3.0	7
267	Antiretroviral treatmentâ€based cost saving interventions may offset expenses for new patients and earlier treatment start. HIV Medicine, 2014, 15, 165-174.	2.2	18
268	Spikeâ€in <scp>SILAC</scp> proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis <scp>C</scp> infections with hepatic iron overload. Proteomics, 2014, 14, 1107-1115.	2.2	13
269	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	3.0	6
270	Characterization of distinct sub-cellular location of transglutaminase type II: changes in intracellular distribution in physiological and pathological states. Cell and Tissue Research, 2014, 358, 793-805.	2.9	43

#	Article	IF	CITATIONS
271	The spermidine analogue GC7 (N1-guanyl-1,7-diamineoheptane) induces autophagy through a mechanism not involving the hypusination of eIF5A. Amino Acids, 2014, 46, 2767-2776.	2.7	22
272	Myocardial and microvascular inflammation/infection in patients with HIV-associated pulmonary artery hypertension. Aids, 2014, 28, 2541-2549.	2.2	18
273	Autophagy plays an important role in the containment of HIV-1 in nonprogressor-infected patients. Autophagy, 2014, 10, 1167-1178.	9.1	70
274	Molecular characterization of hepatitis A outbreak in the province of Rome, Lazio region, Italy, January–July 2013. Microbes and Infection, 2014, 16, 362-366.	1.9	5
275	Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with immune activation markers. Clinical Microbiology and Infection, 2014, 20, O157-O166.	6.0	20
276	Evaluation in a clinical setting of the performances of a new rapid confirmatory assay for $HIV1/2$ serodiagnosis. Journal of Clinical Virology, 2014, 61, 166-169.	3.1	11
277	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 735-741.	3.0	16
278	Hepatitis C virus treatment revolution: need for close monitoring. Clinical Microbiology and Infection, 2014, 20, O790-O791.	6.0	6
279	A Large Epidemic of Hepatitis B in Serbia: An Integrated Model for Outbreak Investigations in Healthcare Settings. Infection Control and Hospital Epidemiology, 2014, 35, 732-735.	1.8	3
280	Cellular and Humoral Cross-Immunity against Two H3N2v Influenza Strains in Presumably Unexposed Healthy and HIV-Infected Subjects. PLoS ONE, 2014, 9, e105651.	2.5	5
281	Measles outbreak on a cruise ship in the western Mediterranean, February 2014, preliminary report. Eurosurveillance, 2014, 19, .	7.0	22
282	Letter to the editor: Management of patients with Ebola virus disease in Europe: high-level isolation units should have a key role. Eurosurveillance, 2014, 19, 20993.	7.0	6
283	A Large Epidemic of Hepatitis B in Serbia: An Integrated Model for Outbreak Investigations in Healthcare Settings. Infection Control and Hospital Epidemiology, 2014, 35, 732-735.	1.8	1
284	Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach. New Microbiologica, 2014, 37, 263-76.	0.1	5
285	Acute rifampicin-associated interstitial tubulopathy in a patient with pulmonary tuberculosis: a case report. Journal of Medical Case Reports, 2013, 7, 106.	0.8	14
286	Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study. BMC Infectious Diseases, 2013, 13, 317.	2.9	21
287	Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infectious Diseases, 2013, 13, 217.	2.9	63
288	Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients. Virus Research, 2013, 177, 205-208.	2.2	18

#	Article	IF	CITATIONS
289	HIV-1 drug resistance in recently HIV-infected pregnant mother's naÃ⁻ve to antiretroviral therapy in Dodoma urban, Tanzania. BMC Infectious Diseases, 2013, 13, 439.	2.9	14
290	Heterogeneity of West Nile virus genotype 1a in Italy, 2011. Journal of General Virology, 2013, 94, 314-317.	2.9	5
291	AIDS and HIV Infection after Thirty Years. AIDS Research and Treatment, 2013, 2013, 1-3.	0.7	1
292	Biosafety Level-4 Laboratories in Europe: Opportunities for Public Health, Diagnostics, and Research. PLoS Pathogens, 2013, 9, e1003105.	4.7	19
293	Strengthening tuberculosis diagnosis in a low-resource setting: experience learned in Dodoma, Tanzania. Journal of Infection in Developing Countries, 2013, 7, 676-679.	1.2	5
294	Appropriateness of Surgical Antimicrobial Prophylaxis in the Latium Region of Italy, 2008: A Multicenter Study. Surgical Infections, 2013, 14, 381-384.	1.4	16
295	The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. BMC Infectious Diseases, 2013, 13, 473.	2.9	38
296	The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing. PLoS ONE, 2013, 8, e53603.	2.5	14
297	HIV treatment as prevention: population effect vs. individual protection?. Annali Di Igiene: Medicina Preventiva E Di Comunita, 2013, 25, 93-7.	0.7	1
298	Biosecurity Measures in 48 Isolation Facilities Managing Highly Infectious Diseases. Biosecurity and Bioterrorism, 2012, 10, 208-214.	1.2	6
299	Impact of Previous ART and of ART Initiation on Outcome of HIV-Associated Tuberculosis. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	15
300	HIV incidence among men who have sex with men prescribed postexposure prophylaxis. Aids, 2012, 26, 1581-1583.	2.2	5
301	Seroprevalence of dengue infection: a cross-sectional survey in mainland Tanzania and on Pemba Island, Zanzibar. International Journal of Infectious Diseases, 2012, 16, e44-e46.	3.3	49
302	Accuracy of indirect haemagglutination and western blot assays for the detection of anti-Schistosoma antibodies in non-severe febrile patients in two Tanzanian hospitals. Scandinavian Journal of Infectious Diseases, 2012, 44, 453-458.	1.5	7
303	Personal Protective Equipment Management and Policies: European Network for Highly Infectious Diseases Data from 48 Isolation Facilities in 16 European Countries. Infection Control and Hospital Epidemiology, 2012, 33, 1008-1016.	1.8	18
304	Ferritin Heavy Chain Is the Host Factor Responsible for HCV-Induced Inhibition of apoB-100 Production and Is Required for Efficient Viral Infection. Journal of Proteome Research, 2012, 11, 2786-2797.	3.7	21
305	Liver Protein Profiling in Chronic Hepatitis C: Identification of Potential Predictive Markers for Interferon Therapy Outcome. Journal of Proteome Research, 2012, 11, 717-727.	3.7	17
306	Monophyletic outbreak of Hepatitis A involving HIV-infected men who have sex with men, Rome, Italy 2008–2009. Journal of Clinical Virology, 2012, 54, 26-29.	3.1	44

#	Article	IF	CITATIONS
307	HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infectious Diseases, 2012, 12, 65.	2.9	14
308	Diagnostic issues and capabilities in 48 isolation facilities in 16 European countries: data from EuroNHID surveys. BMC Research Notes, 2012, 5, 527.	1.4	5
309	Ultraâ€deep sequencing reveals hidden HIVâ€1 minority lineages and shifts of viral population between the main cellular reservoirs of the infection after therapy interruption. Journal of Medical Virology, 2012, 84, 839-844.	5.0	12
310	Autophagy Protects Cells From HCV-Induced Defects in Lipid Metabolism. Gastroenterology, 2012, 142, 644-653.e3.	1.3	66
311	Improvement of Tuberculosis Laboratory Capacity on Pemba Island, Zanzibar: A Health Cooperation Project. PLoS ONE, 2012, 7, e44109.	2.5	4
312	The European Virus Archive: A new resource for virology research. Antiviral Research, 2012, 95, 167-171.	4.1	8
313	Infection control practices in facilities for highly infectious diseases across Europe. Journal of Hospital Infection, 2012, 81, 184-191.	2.9	14
314	Infection control management of patients with suspected highly infectious diseases in emergency departments: data from a survey in 41 facilities in 14 European countries. BMC Infectious Diseases, 2012, 12, 27.	2.9	32
315	Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. BMC Health Services Research, 2012, 12, 38.	2.2	0
316	Viral hemorrhagic fevers: advancing the level of treatment. BMC Medicine, 2012, 10, 31.	5.5	39
317	High-level tolerance to triclosan may play a role in Pseudomonas aeruginosa antibiotic resistance in immunocompromised hosts: evidence from outbreak investigation. BMC Research Notes, 2012, 5, 43.	1.4	26
318	Hospital Cluster of HBV Infection: Molecular Evidence of Patient-to-Patient Transmission through Lancing Device. PLoS ONE, 2012, 7, e33122.	2.5	8
319	High HIV prevalence in male patients with acute hepatitis A in the Rome metropolitan area, Italy 2002–2008. Journal of Hepatology, 2011, 54, 1102-1106.	3.7	11
320	Retrospective Investigation of an Influenza A/H1N1pdm Outbreak in an Italian Military Ship Cruising in the Mediterranean Sea, May-September 2009. PLoS ONE, 2011, 6, e15933.	2.5	15
321	Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. Aids, 2011, 25, 611-617.	2.2	40
322	Analysis of coâ€receptor usage of circulating viral and proviral HIV genome quasispecies by ultraâ€deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clinical Microbiology and Infection, 2011, 17, 725-731.	6.0	32
323	IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infectious Diseases, 2011, 11, 135.	2.9	74
324	Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infectious Diseases, 2011, 11, 140.	2.9	47

#	Article	IF	Citations
325	Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Medicine, 2011, 9, 36.	5.5	78
326	Deep Sequencing of Plasma and Proviral HIV-1 to Establish Coreceptor Usage: What Is the Clinical Impact of the Quasispecies Distribution?. Journal of Infectious Diseases, 2011, 204, 971-973.	4.0	4
327	Molecular Epidemiology of a Pseudomonas aeruginosa Hospital Outbreak Driven by a Contaminated Disinfectant-Soap Dispenser. PLoS ONE, 2011, 6, e17064.	2.5	79
328	Design and clinical application of a molecular method for detection and typing of the influenza A/H1N1pdm virus. Journal of Virological Methods, 2010, 163, 486-488.	2.1	11
329	The prevalence of antibodies to human herpesvirus 8 and hepatitis B virus in patients in two hospitals in Tanzania. Journal of Medical Virology, 2010, 82, 1569-1575.	5.0	14
330	IFN- \hat{l}^3 , but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. Journal of Infection, 2010, 61, 133-143.	3.3	57
331	Molecular epidemiology of a hepatitis C virus epidemic in a haemodialysis unit: outbreak investigation and infection outcome. BMC Infectious Diseases, 2010, 10, 257.	2.9	27
332	Alkhurma Hemorrhagic Fever in Travelers Returning from Egypt, 2010. Emerging Infectious Diseases, 2010, 16, 1979-1982.	4.3	63
333	Association of Profoundly Impaired Immune Competence in H1N1vâ€Infected Patients with a Severe or Fatal Clinical Course. Journal of Infectious Diseases, 2010, 202, 681-689.	4.0	50
334	Frequency of Detection of Upper Respiratory Tract Viruses in Patients Tested for Pandemic H1N1/09 Viral Infection. Journal of Clinical Microbiology, 2010, 48, 3383-3385.	3.9	30
335	Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review. International Journal of Infectious Diseases, 2010, 14, e283-e291.	3.3	41
336	Gruppo Italiano di Studio sulle Infezioni Gravi – GISIG 3: controversial issues of severe bacterial infections due to multidrug-resistant Gram-positive bacteria: introduction by the National Coordinators. International Journal of Infectious Diseases, 2010, 14, S1.	3.3	0
337	Methicillin-resistant Staphylococcus aureus: the superbug. International Journal of Infectious Diseases, 2010, 14, S7-S11.	3.3	159
338	Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. International Journal of Infectious Diseases, 2010, 14, S67-S77.	3.3	53
339	Consensus document on controversial issues in the diagnosis and treatment of bloodstream infections and endocarditis. International Journal of Infectious Diseases, 2010, 14, S23-S38.	3.3	9
340	Consensus document on controversial issues in the treatment of complicated skin and skin-structure infections. International Journal of Infectious Diseases, 2010, 14, S39-S53.	3.3	25
341	Consensus document on controversial issues for the treatment of hospital-associated pneumonia. International Journal of Infectious Diseases, 2010, 14, S55-S65.	3.3	5
342	Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. International Journal of Infectious Diseases, 2010, 14, S79-S92.	3.3	102

#	Article	IF	CITATIONS
343	A multi-society position paper on the prevention and management of nosocomial and severe infections: the Italian Society for Infectious Diseases, the Italian Multidisciplinary Society of Hospital Infections, the Italian Society of Chemotherapy, the Italian Society of Respiratory Medicine, the Italian Society of Clinical Microbiology, the Italian Society of Microbiology, and GISIG (Italian Study Group) Tj ETQq1 1 0.3	3.3 .784314 rg	1 gBT /Overloc
344	Evolutionary pattern of pandemic influenza (H1N1) 2009 virus in the late phases of the 2009 pandemic PLOS Currents, 2010, 2, RRN1149.	1.4	18
345	Is IP-10 an Accurate Marker for Detecting M. tuberculosis-Specific Response in HIV-Infected Persons?. PLoS ONE, 2010, 5, e12577.	2.5	73
346	Retrospective screening of solid organ donors in Italy, 2009, reveals unpredicted circulation of West Nile virus. Eurosurveillance, 2010, 15 , .	7. O	24
347	Cat-to-Human Orthopoxvirus Transmission, Northeastern Italy. Emerging Infectious Diseases, 2009, 15, 499-500.	4.3	24
348	Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus may be fully replication competent. Aids, 2009, 23, 2541-2543.	2.2	17
349	Crimean-Congo Hemorrhagic Fever, Southwestern Bulgaria. Emerging Infectious Diseases, 2009, 15, 983-985.	4.3	44
350	European Perspective of 2-Person Rule for Biosafety Level 4 Laboratories. Emerging Infectious Diseases, 2009, 15, 1858a-1860.	4.3	3
351	Use of Massively Parallel Ultradeep Pyrosequencing To Characterize the Genetic Diversity of Hepatitis B Virus in Drug-Resistant and Drug-Naive Patients and To Detect Minor Variants in Reverse Transcriptase and Hepatitis B S Antigen. Journal of Virology, 2009, 83, 1718-1726.	3.4	143
352	Isolation rooms for highly infectious diseases: an inventory of capabilities in European countries. Journal of Hospital Infection, 2009, 73, 15-23.	2.9	26
353	Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Medicine, 2009, 7, 15.	5.5	76
354	Transgenic chloroplasts are efficient sites for highâ€yield production of the vaccinia virus envelope protein A27L in plant cellsâ€. Plant Biotechnology Journal, 2009, 7, 577-591.	8.3	35
355	Training health care workers to face highly infectious diseases. Clinical Microbiology and Infection, 2009, 15, 740-742.	6.0	10
356	EuroNHID checklists for the assessment of high-level isolation units and referral centres for highly infectious diseases: results from the pilot phase of a European survey. Clinical Microbiology and Infection, 2009, 15, 711-719.	6.0	21
357	Facing the threat of highly infectious diseases in Europe: the need for a networking approach. Clinical Microbiology and Infection, 2009, 15, 706-710.	6.0	4
358	The European network of Biosafety-Level-4 laboratories: enhancing European preparedness for new health threats. Clinical Microbiology and Infection, 2009, 15, 720-726.	6.0	22
359	Risk of Kaposi Sarcoma after Solid-Organ Transplantation: Multicenter Study in 4767 Recipients in Italy, 1970–2006. Transplantation Proceedings, 2009, 41, 1227-1230.	0.6	36
360	Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology, 2009, 6, 15.	2.0	89

#	Article	IF	Citations
361	Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases. Lancet Infectious Diseases, The, 2009, 9, 45-56.	9.1	97
362	Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease. Lancet Infectious Diseases, The, 2009, 9, 301-311.	9.1	69
363	Healthcare-Associated Infection in Italy Annual Point-Prevalence Surveys, 2002–2004. Infection Control and Hospital Epidemiology, 2009, 30, 659-665.	1.8	33
364	Accuracy of Malaria Diagnosis by Microscopy, Rapid Diagnostic Test, and PCR Methods and Evidence of Antimalarial Overprescription in Non-Severe Febrile Patients in Two Tanzanian Hospitals. American Journal of Tropical Medicine and Hygiene, 2009, 80, 712-717.	1.4	60
365	Accuracy of malaria diagnosis by microscopy, rapid diagnostic test, and PCR methods and evidence of antimalarial overprescription in non-severe febrile patients in two Tanzanian hospitals. American Journal of Tropical Medicine and Hygiene, 2009, 80, 712-7.	1.4	38
366	Case definition for Ebola and Marburg haemorrhagic fevers: a complex challenge for epidemiologists and clinicians. New Microbiologica, 2009, 32, 359-67.	0.1	19
367	Surgical site infections in Italian Hospitals: a prospective multicenter study. BMC Infectious Diseases, 2008, 8, 34.	2.9	81
368	Networking for infectious-disease emergencies in Europe. Nature Reviews Microbiology, 2008, 6, 564-564.	28.6	8
369	Ebolavirus and Marburgvirus: Insight the Filoviridae family. Molecular Aspects of Medicine, 2008, 29, 151-185.	6.4	84
370	Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. European Journal of Cancer, 2008, 44, 847-853.	2.8	48
371	Role of hepatitis B virus, hepatitis D virus and other determinants on suppression of hepatitis C viraemia in HIV infected patients with chronic HCV infection: A longitudinal evaluation. Scandinavian Journal of Infectious Diseases, 2008, 40, 928-934.	1.5	10
372	Ageing with HIV: newly diagnosed older adults in Italy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 419-425.	1.2	39
373	Noninvasive positive-pressure ventilation. Cmaj, 2008, 178, 597-598.	2.0	0
374	Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries. Occupational and Environmental Medicine, 2008, 65, 446-451.	2.8	52
375	Presence of the A226V Mutation in Autochthonous and Imported Italian Chikungunya Virus Strains. Clinical Infectious Diseases, 2008, 47, 428-429.	5. 8	42
376	Erratum-II. Current Medicinal Chemistry, 2008, 15, 3280-3280.	2.4	5
377	Therapeutic Drug Monitoring in the Management of HIV-Infected Patients. Current Medicinal Chemistry, 2008, 15, 1925-1939.	2.4	12
378	Rapid and Biologically Safe Procedures for the Evaluation of Antigen-Specific T Cell Response to Microbial Pathogens that May be Used in the BSL-3 and BSL-4 Environment. Applied Biosafety, 2008, 13, 27-30.	0.5	3

#	Article	IF	Citations
379	Cross-subtype Immunity against Avian Influenza in Persons Recently Vaccinated for Influenza. Emerging Infectious Diseases, 2008, 14, 121-128.	4.3	81
380	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. PLoS ONE, 2008, 3, e3417.	2.5	88
381	Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. International Journal of Tuberculosis and Lung Disease, 2008, 12, 146-51.	1.2	68
382	Risk management of febrile respiratory illness in emergency departments. New Microbiologica, 2008, 31, 165-73.	0.1	7
383	Decrease of methicillin resistant Staphylococcus aureus prevalence after introduction of a surgical antibiotic prophylaxis protocol in an Italian hospital. New Microbiologica, 2008, 31, 519-25.	0.1	7
384	Effective Highly Active Antiretroviral Therapy in Patients With Primary HIV-1 Infection Prevents the Evolution of the Avidity of HIV-1-Specific Antibodies. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 145-150.	2.1	32
385	Consent Policies and Rates of HIV Testing. JAMA - Journal of the American Medical Association, 2007, 297, 2478.	7.4	3
386	Should Individuals Who Are Tuberculin Skin Test Negative and Positive to RD1–IFN-γ Assay Receive Preventive Therapy?. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 198a-199.	5.6	5
387	Incidence and Timing of Infections After Liver Transplant in Italy. Transplantation Proceedings, 2007, 39, 1950-1952.	0.6	19
388	Biocontainment Patient Care Units. Biosecurity and Bioterrorism, 2007, 5, 86-86.	1.2	0
389	Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respiratory Research, 2007, 8, 5.	3.6	54
390	Impact of hepatitis C virus infection on lifestyle. World Journal of Gastroenterology, 2007, 13, 2722.	3.3	11
391	A curriculum for training healthcare workers in the management of highly infectious diseases. Eurosurveillance, 2007, 12, 5-6.	7.0	22
392	Rapid detection and quantification of Chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay. American Journal of Tropical Medicine and Hygiene, 2007, 77, 521-4.	1.4	13
393	Trends in HIV Prevalence Among Pregnant Women in Italy, 1994 to 2002. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 361-364.	2.1	16
394	Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clinical Microbiology and Infection, 2006, 12, 544-550.	6.0	78
395	Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 831, 258-266.	2.3	124
396	Bcl-2 inhibits the caspase-dependent apoptosis induced by SARS-CoV without affecting virus replication kinetics. Archives of Virology, 2006, 151, 369-377.	2.1	40

#	Article	IF	Citations
397	Biological weapons. Cellular and Molecular Life Sciences, 2006, 63, 2213-2222.	5.4	21
398	Clustered Cases of Pneumonia among Healthcare Workers over a 1-year Period in Three Italian Hospitals: Applying the WHO SARS Alert. Infection, 2006, 34, 219-221.	4.7	3
399	Anti–Severe Acute Respiratory Syndrome Coronavirus Immune Responses: The Role Played by Vγ9Vδ2 T Cells. Journal of Infectious Diseases, 2006, 193, 1244-1249.	4.0	78
400	Access to gynecological services and Papanicolau tests in HIV-infected Italian women: A questionnaire survey. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2006, 18, 376-378.	1.2	5
401	Partnership of HIV-Infected Women and Health Status. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 502-503.	2.1	0
402	The epidemiology of recurrent bacterial pneumonia in people with AIDS in Europe. Epidemiology and Infection, 2005, 133, 237-243.	2.1	3
403	Prevalence and risk factors for human immunodeficiency virus–associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort. Journal of NeuroVirology, 2005, 11, 265-273.	2.1	117
404	Predisposition of antiretroviral prophylaxis for solid organ transplantation in human immunodeficiency virus-infected patients. Transplant Infectious Disease, 2005, 7, 171-172.	1.7	1
405	HIV/AIDS in 2004: the epidemiologist's point of view. Cell Death and Differentiation, 2005, 12, 837-844.	11.2	2
406	The Initial Hospital Response to an Epidemic. Archives of Medical Research, 2005, 36, 706-712.	3.3	12
407	Rapid, differential diagnosis of orthopox- and herpesviruses based upon real-time PCR product melting temperature and restriction enzyme analysis of amplicons. Journal of Virological Methods, 2005, 129, 97-100.	2.1	18
408	Knowledge and use of papanicolaou test among HIV-positive women. International Journal of Cancer, 2005, 115, 1009-1010.	5.1	5
409	HIV Infection among Low-Risk First Lifetime Testers in Rome, 1990?2000. Infection, 2005, 33, 61-65.	4.7	2
410	T-Cell Response Profiling to Biological Threat Agents Including the Sars Coronavirus. International Journal of Immunopathology and Pharmacology, 2005, 18, 525-530.	2.1	29
411	Efficacy of Cerebrospinal Fluid (CSF)–Penetrating Antiretroviral Drugs against HIV in the Neurological Compartment: Different Patterns of Phenotypic Resistance in CSF and Plasma. Clinical Infectious Diseases, 2005, 41, 1787-1793.	5.8	106
412	Screening for Human Herpesvirus 8 Antibodies in Italian Organ Transplantation Centers. Clinical Infectious Diseases, 2005, 40, 203-205.	5.8	13
413	Postexposure HIV Prophylaxis Regimen. Clinical Infectious Diseases, 2005, 40, 205-206.	5.8	4
414	A molecular beacon, bead-based assay for the detection of nucleic acids by flow cytometry. Nucleic Acids Research, 2005, 33, e13-e13.	14.5	76

#	Article	IF	Citations
415	Neurocognitive Impairment and Survival in a Cohort of HIV-Infected Patients Treated with HAART. AIDS Research and Human Retroviruses, 2005, 21, 706-713.	1.1	104
416	Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive HIV-Infected Individuals. Clinical Infectious Diseases, 2005, 40, e101-e109.	5.8	46
417	Possible Child-to-Mother Transmission of HIV by Breastfeeding. JAMA - Journal of the American Medical Association, 2005, 294, 2297.	7.4	6
418	Hospital preparedness and management of patients affected by viral haemorrhagic fever or smallpox at the Lazzaro Spallanzani Institute, Italy. Eurosurveillance, 2005, 10, 1-2.	7.0	9
419	Human Herpesvirus 8 and Pulmonary Hypertension. Emerging Infectious Diseases, 2005, 11, 1480-1482.	4.3	30
420	Human herpesvirus 8 and pulmonary hypertension. Emerging Infectious Diseases, 2005, 11, 1480-2.	4.3	13
421	Hospital preparedness and management of patients affected by viral haemorrhagic fever or smallpox at the Lazzaro Spallanzani Institute, Italy. Eurosurveillance, 2005, 10, 36-9.	7.0	6
422	Infection with Epstein-Barr virus and cancer: an epidemiological review. Journal of Biological Regulators and Homeostatic Agents, 2005, 19, 63-70.	0.7	14
423	Conventional Protein Kinase C Inhibition Prevents Alpha Interferon-Mediated Hepatitis C Virus Replicon Clearance by Impairing STAT Activation. Journal of Virology, 2004, 78, 12809-12816.	3.4	21
424	Hepatic Safety and Postexposure Prophylaxis. Clinical Infectious Diseases, 2004, 39, 1083-1084.	5.8	3
425	Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. European Respiratory Journal, 2004, 24, 11-17.	6.7	53
426	Delayed Presentation and Late Testing for HIV: Demographic and Behavioral Risk Factors in a Multicenter Study in Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 951-959.	2.1	149
427	Comparison of LCx with Other Current Viral Load Assays for Detecting and Quantifying Human Immunodeficiency Virus Type 1 RNA in Patients Infected with the Circulating Recombinant Form A/G (CRF02). Journal of Clinical Microbiology, 2004, 42, 811-815.	3.9	16
428	Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. International Journal of STD and AIDS, 2004, 15, 254-259.	1.1	84
429	Drug-Resistant Tuberculosis in HIV-Infected Persons: Italy 1999?2000. Infection, 2004, 32, 328-332.	4.7	5
430	HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. Journal of Hepatology, 2004, 40, 831-836.	3.7	39
431	SARS and masks. Journal of Hospital Infection, 2004, 56, 73-74.	2.9	11
432	Benefits of a rapid HIV test for evaluation of the source patient after occupational exposure of healthcare workers. Journal of Hospital Infection, 2004, 57, 179-182.	2.9	21

#	Article	IF	Citations
433	Highly Active Antiretroviral Therapy Restores CD4+ V?? T-Cell Repertoire in Patients With Primary Acute HIV Infection But Not in Treatment-Naive HIV+ Patients With Severe Chronic Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 213-222.	2.1	25
434	Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart. Antiviral Therapy, 2004, 9, 291-296.	1.0	32
435	Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems. Antiviral Therapy, 2004, 9, 743-752.	1.0	16
436	The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?. Antiviral Therapy, 2004, 9, 811-817.	1.0	11
437	Post-Exposure Prophylaxis of HIV Infection in Healthcare Workers: Recommendations for the European Setting. European Journal of Epidemiology, 2003, 19, 577-584.	5.7	22
438	Anthrax, Botulism and Tularemia in Italy. Infection, 2003, 31, 128-129.	4.7	4
439	Hepatitis C: virus, host, disease. Cell Death and Differentiation, 2003, 10, S1-S2.	11.2	2
440	Transglutaminase Type II Plays a Protective Role in Hepatic Injury. American Journal of Pathology, 2003, 162, 1293-1303.	3.8	68
441	Neuroleukin inhibition sensitises neuronal cells to caspase-dependent apoptosis. Biochemical and Biophysical Research Communications, 2003, 302, 448-453.	2.1	22
442	PCR Assay To Detect Bacillus anthracis Spores in Heat-Treated Specimens. Journal of Clinical Microbiology, 2003, 41, 896-899.	3.9	50
443	Infection with Hepatitis C Virus Transmitted by Accidental Needlesticks. Clinical Infectious Diseases, 2003, 37, 1718-1718.	5.8	9
444	Neurocognitive Performance and Quality of Life in Patients with HIV Infection. AIDS Research and Human Retroviruses, 2003, 19, 643-652.	1.1	107
445	Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis. Aids, 2003, 17, 1988-1990.	2.2	14
446	Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS. Aids, 2003, 17, 2109-2116.	2.2	43
447	Identification of Early Secretory Antigen Target-6 Epitopes for the Immunodiagnosis of Active Tuberculosis. Molecular Medicine, 2003, 9, 105-111.	4.4	49
448	Flow Cytometry and T-Cell Response Monitoring after Smallpox Vaccination. Emerging Infectious Diseases, 2003, 9, 1468-1470.	4.3	12
449	Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Molecular Medicine, 2003, 9, 105-11.	4.4	19
450	Prevalence of nosocomial infections in 15 Italian hospitals: first point prevalance study for the INF-NOS project. Infection, 2003, 31 Suppl 2, 10-5.	4.7	15

#	Article	IF	CITATIONS
451	Underevaluation of HIV-1 Plasma Viral Load by a Commercially Available Assay in a Cluster of Patients Infected With HIV-1 A/G Circulating Recombinant Form (CRFO2). Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 488-494.	2.1	26
452	Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. Aids, 2002, 16, 2431-2438.	2.2	29
453	Behavioral Correlates of Adherence to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S145-S148.	2.1	30
454	Simple and Reliable Method for Detection and Genotyping of Hepatitis C Virus RNA in Dried Blood Spots Stored at Room Temperature. Journal of Clinical Microbiology, 2002, 40, 3512-3514.	3.9	36
455	Nosocomial Bloodstream Infections among Human Immunodeficiency Virus-Infected Patients: Incidence and Risk Factors. Clinical Infectious Diseases, 2002, 34, 677-685.	5.8	50
456	Acute Human Immunodeficiency Virus Replication Causes a Rapid and Persistent Impairment of VÎ ³ 9VÎ ² T Cells in Chronically Infected Patients Undergoing Structured Treatment Interruption. Journal of Infectious Diseases, 2002, 186, 847-850.	4.0	46
457	Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. Aids, 2002, 16, 619-624.	2.2	34
458	INTERLEUKIN (IL)-4 INHIBITS PHORBOL-ESTER INDUCED HIV-1 EXPRESSION IN CHRONICALLY INFECTED U1 CELLS INDEPENDENTLY FROM THE AUTOCRINE EFFECT OF ENDOGENOUS TUMOUR NECROSIS FACTOR-α, IL-1β, AND IL-1 RECEPTOR ANTAGONIST. Cytokine, 2002, 17, 28-35.	3.2	10
459	Monophyletic HIV Type 1 CRF02-AG in a Nosocomial Outbreak in Benghazi, Libya. AIDS Research and Human Retroviruses, 2002, 18, 727-732.	1.1	31
460	Factors Related to Virologic Failure among HIV-Positive Injecting Drug Users Treated with Combination Antiretroviral Therapy Including Two Nucleoside Reverse Transcriptase Inhibitors and Nevirapine. AIDS Patient Care and STDs, 2002, 16, 67-73.	2.5	31
461	Anthrax toxin: a tripartite lethal combination 1. FEBS Letters, 2002, 531, 384-388.	2.8	116
462	A Nosocomial and Occupational Cluster of Hepatitis A Virus Infection in a Pediatric Ward. Infection Control and Hospital Epidemiology, 2002, 23, 343-345.	1.8	20
463	Computer-Based Design of an HLA-Haplotype and HIV-Clade Independent Cytotoxic T-Lymphocyte (CTL) Assay for Monitoring HIV-Specific Immunity. Molecular Medicine, 2002, 8, 798-807.	4.4	13
464	Pulmonary Tuberculosis in HIV-Infected Patients Presenting with Normal Chest Radiograph and Negative Sputum Smear. Infection, 2002, 30, 68-74.	4.7	61
465	Prevalence, Determinants, and Molecular Epidemiology of Streptococcus pneumoniae Isolates Colonizing the Nasopharynx of Healthy Children in Rome. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 181-188.	2.9	36
466	Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Acta Psychiatrica Scandinavica, 2002, 106, 20-26.	4.5	57
467	High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. Aids, 2002, 16, 1976-1979.	2.2	25
468	Computer-based design of an HLA-haplotype and HIV-clade independent cytotoxic T-lymphocyte assay for monitoring HIV-specific immunity. Molecular Medicine, 2002, 8, 798-807.	4.4	5

#	Article	IF	CITATIONS
469	Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals. Journal of Biological Regulators and Homeostatic Agents, 2002, 16, 37-43.	0.7	5
470	Risk management of HBsAg or anti-HCV positive healthcare workers in hospital. Digestive and Liver Disease, 2001, 33, 795-802.	0.9	25
471	Prevalence of infected patients and understaffing have a rolein hepatitis C virus transmission in dialysis. American Journal of Kidney Diseases, 2001, 37, 1004-1010.	1.9	131
472	Risk of Exposure to Bloodborne Infection for Italian Healthcare Workers, by Job Category and Work Area. Infection Control and Hospital Epidemiology, 2001, 22, 206-210.	1.8	66
473	Changing Patterns of "Hospital-at-Home" Care Use by Persons with AIDS in the Era of Combination Antiretroviral Therapy. AIDS Patient Care and STDs, 2001, 15, 625-632.	2.5	1
474	Occupational exposure in healthcare workers: an Italian study of occupational risk of HIV and other blood-borne viral infections. British Journal of Infection Control, 2001, 2, 15-17.	0.4	1
475	\hat{V} î T Lymphocytes Expressing a Th1 Phenotype Are the Major \hat{I} î T Cell Subset Infiltrating the Liver of HCV-infected Persons. Molecular Medicine, 2001, 7, 11-19.	4.4	50
476	HIV Infection Among Foreign Transsexual Sex Workers in Rome. Sexually Transmitted Diseases, 2001, 28, 405-411.	1.7	35
477	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. Aids, 2001, 15, 1483-1491.	2.2	175
478	Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. European Respiratory Journal, 2001, 18, 369-375.	6.7	12
479	Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis After Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 326-331.	2.1	22
480	Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis After Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 326-331.	2.1	71
481	Changes in Neurocognitive Performance in a Cohort of Patients Treated With HAART for 3 Years. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 19-27.	2.1	74
482	Increasing Prevalence of Non–Clade B HIV-1 Strains in Heterosexual Men and Women, as Monitored by Analysis of Reverse Transcriptase and Protease Sequences. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 499-505.	2.1	41
483	HHV-8 Shedding Among HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 103-104.	2.1	7
484	Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. Journal of NeuroVirology, 2001, 7, 323-328.	2.1	68
485	Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. Journal of NeuroVirology, 2001, 7, 364-368.	2.1	64
486	Clinical Manifestation of HIVâ€Related Pulmonary Hypertension. Annals of the New York Academy of Sciences, 2001, 946, 223-235.	3.8	18

#	Article	IF	CITATIONS
487	Risk of HIV and Other Bloodâ€Borne Infections in the Cardiac Setting. Annals of the New York Academy of Sciences, 2001, 946, 291-309.	3.8	26
488	Presence of anti- tissue' transglutaminase antibodies in inflammatory intestinal diseases: an apoptosis-associated event?. Cell Death and Differentiation, 2001, 8, 767-770.	11.2	40
489	The Changing Picture of the HIV/AIDS Epidemic. Annals of the New York Academy of Sciences, 2001, 946, 1-12.	3.8	29
490	Catheterâ€Related Bloodstream Infections in HIVâ€Infected Patients. Annals of the New York Academy of Sciences, 2001, 946, 274-290.	3.8	32
491	Increasing Prevalence of Non–Clade B HIV-1 Strains in Heterosexual Men and Women, as Monitored by Analysis of Reverse Transcriptase and Protease Sequences. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 499-505.	2.1	69
492	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 445-449.	2.1	405
493	$\hat{I}^3\hat{I}$ T Cell Activation by Chronic HIV Infection May Contribute to Intrahepatic V \hat{I}' 1 Compartmentalization and Hepatitis C Virus Disease Progression Independent of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 1357-1363.	1.1	31
494	Transmission of Hepatitis C Virus in a Gynecological Surgery Setting. Journal of Clinical Microbiology, 2001, 39, 2860-2863.	3.9	57
495	Secondary Mutations in the Protease Region of Human Immunodeficiency Virus and Virologic Failure in Drugâ€Naive Patients Treated with Protease Inhibitor–Based Therapy. Journal of Infectious Diseases, 2001, 184, 983-991.	4.0	104
496	Sexual behaviour of heterosexual individuals with HIV infection naive for antiretroviral therapy in Italy. Sexually Transmitted Infections, 2001, 77, 130-134.	1.9	9
497	Natural T Cell Immunity to Intracellular Pathogens and Nonpeptidic Immunoregulatory Drugs. Current Molecular Medicine, 2001, 1, 137-151.	1.3	15
498	Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. Aids, 2001, 15, 1579-1581.	2.2	67
499	Estimating duration of HIV infection with CD4 cell count and HIV-1 RNA at presentation. Aids, 2001, 15, 2201-2203.	2.2	9
500	Sexual Transmission of Transfusion-Transmitted Virus. Sexually Transmitted Diseases, 2001, 28, 298-299.	1.7	1
501	Changes in Neurocognitive Performance in a Cohort of Patients Treated With HAART for 3 Years. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 19-27.	2.1	1
502	Vdelta1 T lymphocytes expressing a Th1 phenotype are the major gammadelta T cell subset infiltrating the liver of HCV-infected persons. Molecular Medicine, 2001, 7, 11-9.	4.4	29
503	Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. Journal of Biological Regulators and Homeostatic Agents, 2001, 15, 238-42.	0.7	11
504	Risks faced by laboratory workers in the AIDS era. Journal of Biological Regulators and Homeostatic Agents, 2001, 15, 243-8.	0.7	2

#	Article	IF	CITATIONS
505	The model of response to viral haemorrhagic fevers of the National Institute for Infectious Diseases "Lazzaro Spallanzani". Journal of Biological Regulators and Homeostatic Agents, 2001, 15, 314-21.	0.7	1
506	Cervicovaginal shedding of TT virus in HIV-infected women. Journal of Human Virology, 2001, 4, 343-5.	0.8	4
507	Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 56-62.	2.1	22
508	Increasing Proportion of Late Diagnosis of HIV Infection Among Patients With AIDS in Italy Following Introduction of Combination Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 71-76.	2.1	28
509	Effect of Antiretroviral Agents on T-Lymphocyte Subset Counts in Healthy HIV-Negative Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 440-443.	2.1	4
510	Cancer risk among men with, or at risk of, HIV infection in southern Europe. Aids, 2000, 14, 553-559.	2.2	105
511	Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. Aids, 2000, 14, 1985-1991.	2.2	139
512	Effect of Antiretroviral Agents on T-Lymphocyte Subset Counts in Healthy HIV-Negative Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 440-443.	2.1	4
513	Prevalence of HHV-8 infection among cancer patients in Sicily. , 2000, 86, 448-449.		8
514	Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?. European Journal of Epidemiology, 2000, 16, 919-926.	5.7	8
515	Prevalence of Antibodies to Human Herpesvirus 8 in Children from Sardinia and Croatia. Infection, 2000, 28, 336-338.	4.7	3
516	HIV Infections: The Global Epidemiology and Goals for Vaccine Research. Molecular Medicine, 2000, 6, 69-85.	4.4	4
517	Increasing Proportion of Late Diagnosis of HIV Infection Among Patients With AIDS in Italy Following Introduction of Combination Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 71-76.	2.1	63
518	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral na \tilde{A} ve patients. Aids, 2000, 14, 499-507.	2.2	483
519	Using the Number of Koilocytes To Predict HIV Serostatus in Women with HPV-Associated SIL. Acta Cytologica, 2000, 44, 1000-1004.	1.3	1
520	Sexual behaviour of women living with HIV/AIDS na \tilde{A} -ve for antiretroviral therapy: The ICONA-BEHEPI Study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2000, 12, 789-795.	1,2	2
521	Transient Detection of Plasma HIV-1 RNA During Postexposure Prophylaxis. Infection Control and Hospital Epidemiology, 2000, 21, 529-531.	1.8	8
522	Molecular Epidemiology of an Outbreak of Fulminant Hepatitis B. Journal of Clinical Microbiology, 2000, 38, 2975-2981.	3.9	40

#	Article	IF	CITATIONS
523	Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes. Journal of Leukocyte Biology, 2000, 68, 429-35.	3.3	35
524	Occupational Human Immunodeficiency Virus Infection in Health Care Workers: Worldwide Cases Through September 1997. Clinical Infectious Diseases, 1999, 28, 365-383.	5.8	158
525	Negative Predictors of Survival in HIV-Infected Patients with Culture-Confirmed Pulmonary Tuberculosis. Infection, 1999, 27, 331-334.	4.7	11
526	Nosocomial infections in HIV infected patients. Aids, 1999, 13, 599-605.	2.2	17
527	Surveillance of occupational exposure to bloodborne pathogens in health care workers: the Italian national programme. Eurosurveillance, 1999, 4, 33-36.	7.0	49
528	Temporal trends in reasons for and result of HIV-testing among women in Rome, Italy. European Journal of Epidemiology, 1998, 14, 433-437.	5.7	8
529	Newly diagnosed HIV infections among pregnant women and their partners., 1998, 14, 521-522.		1
530	The Italian quality control study for evaluation of CD4 cells in centres involved in the treatment of HIV-1 patients. Clinical and Experimental Immunology, 1998, 111, 564-573.	2.6	10
531	Women attending human immunodeficiency virus counselling and testing site because of pregnancy, and prevalence of newly diagnosed infections. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1998, 79, 51-55.	1.1	0
532	Simultaneous Infection With HIV and Hepatitis C Virus Following Occupational Conjunctival Blood Exposure. JAMA - Journal of the American Medical Association, 1998, 280, 28.	7.4	69
533	HIV-1 diversity in Romania. Aids, 1998, 12, 1079-1085.	2.2	59
534	Peer-Reviewed Articles and Public Health. JAMA - Journal of the American Medical Association, 1998, 280, 292.	7.4	11
535	Hepatitis B Vaccination Coverage among Healthcare Workers in Italy. Infection Control and Hospital Epidemiology, 1998, 19, 789-791.	1.8	15
536	Risk factors for cervical presence of human papillomavirus DNA among women at risk for HIV infection. Epidemiology and Infection, 1998, 121, 173-177.	2.1	15
537	Preventive Therapy for Tuberculosis in HIV-Infected Persons <subtitle>Analysis of Policy Options Based on Tuberculin Status and CD4⁺ Cell Count</subtitle> . Archives of Internal Medicine, 1998, 158, 2112.	3.8	8
538	Hepatitis B Vaccination Coverage among Healthcare Workers in Italy. Infection Control and Hospital Epidemiology, 1998, 19, 789-791.	1.8	9
539	A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure. New England Journal of Medicine, 1997, 337, 1485-1490.	27.0	1,070
540	The changing distribution of HIV infection: HIV surveillance in Lazio, Italy, 1985 through 1994. Lazio HIV Surveillance Collaborative Group American Journal of Public Health, 1997, 87, 1654-1658.	2.7	12

#	Article	IF	Citations
541	Zidovudine toxicity in uninfected healthcare workers. American Journal of Medicine, 1997, 102, 58-62.	1.5	31
542	Determinants of squamous intraepithelial lesions (SIL) on Pap smear: the role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS Collaborative Study Group. European Journal of Epidemiology, 1997, 13, 937-943.	5.7	31
543	HIV infection increases the risk of squamous intra-epithelial lesions in women with HPV infection: An analysis of HPV genotypes., 1997, 72, 982-986.		35
544	Prophylaxis after occupational exposure to HIV. BMJ: British Medical Journal, 1997, 315, 557-558.	2.3	13
545	The Ingelfinger rule. Lancet, The, 1996, 348, 133.	13.7	0
546	Scalpel injury and HIV infection in a surgeon. Lancet, The, 1996, 347, 1042.	13.7	17
547	HIV Infection after Kidney Transplantation. Nephron, 1996, 72, 124-124.	1.8	2
548	Drug Resistance Patterns among Tuberculosis Patients in Rome, 1990-1992. Scandinavian Journal of Infectious Diseases, 1996, 28, 487-491.	1.5	13
549	Temporal and Geographical Trends of Anti-HIV-1 Antibodies Screening Among Newborns in Italy, 1990-1993. Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 63-68.	0.3	11
550	Occupational hepatitis C virus infection in Italian health care workers. Italian Study Group on Occupational Risk of Bloodborne Infections American Journal of Public Health, 1995, 85, 1272-1275.	2.7	47
551	Prevalence and incidence of hepatitis B virus, hepatitis C virus and human immunodeficiency virus among personnel and patients of a psychiatric hospital. European Journal of Epidemiology, 1995, 11, 239-242.	5.7	14
552	Tuberculosis and AIDS: a retrospective, longitudinal, multicentre study of Italian AIDS patients. Journal of Infection, 1995, 30, 269.	3.3	0
553	Hepatitis C Virus Infection in Healthcare Workers. Infection Control and Hospital Epidemiology, 1995, 16, 324-326.	1.8	14
554	Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in health care workers: a multiple regression analysis of risk factors. Journal of Hospital Infection, 1995, 30, 273-281.	2.9	24
555	Risk of hepatitis C seroconversion after occupational exposures in health care workers*1. American Journal of Infection Control, 1995, 23, 273-277.	2.3	186
556	The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting*1. American Journal of Infection Control, 1995, 23, 278-285.	2.3	36
557	Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA - Journal of the American Medical Association, 1995, 274, 143-148.	7.4	177
558	Hepatitis C Virus Infection in Healthcare Workers. Infection Control and Hospital Epidemiology, 1995, 16, 324-326.	1.8	11

#	Article	IF	Citations
559	Device-Specific Risk of Needlestick Injury in Italian Health Care Workers. Obstetrical and Gynecological Survey, 1995, 50, 34-35.	0.4	0
560	Device-Specific Risk of Needlestick Injury in Italian Health Care Workers. JAMA - Journal of the American Medical Association, 1994, 272, 607.	7.4	48
561	Transmission of Zidovudine-Resistant HIV During a Bloody Fight. JAMA - Journal of the American Medical Association, 1994, 272, 433.	7.4	17
562	Pooling of paper-adsorbed blood samples to reduce the cost of anti-HIV testing in epidemiological studies. Infection, 1994, 22, 428-429.	4.7	2
563	Low risk of HCV infection in health care workers. Infection, 1994, 22, 115-115.	4.7	7
564	Use of pooled residual laboratory sera to assess human immunodeficiency virus prevalence among patients in Italy. European Journal of Clinical Microbiology and Infectious Diseases, 1994, 13, 205-211.	2.9	2
565	Tuberculosis and AIDS: a retrospective, longitudinal, multicentre study of Italian AIDS patients. Journal of Infection, 1994, 28, 261-269.	3.3	12
566	Prevalence of hepatitis C antibodies in health-care workers. Lancet, The, 1994, 344, 339-340.	13.7	40
567	Risk of human immunodeficiency virus infection for emergency department workers. Journal of Emergency Medicine, 1994, 12, 737-744.	0.7	14
568	Prevalence of hepatitis C antibodies in health-care workers. Italian Study Group on Blood-borne Occupational Risk in Dialysis. Lancet, The, 1994, 344, 339-40.	13.7	4
569	Device-specific risk of needlestick injury in Italian health care workers. JAMA - Journal of the American Medical Association, 1994, 272, 607-10.	7.4	7
570	Understanding the dynamics of the HIV epidemic among Italian intravenous drug users: a cross-sectional versus a longitudinal approach. Journal of Acquired Immune Deficiency Syndromes, 1994, 7, 500-3.	1.0	10
571	Anti-HIV I antibodies prevalence in parturients through newborn testing: Results of the Italian anonymous serosurvey. European Journal of Epidemiology, 1993, 9, 430-435.	5.7	11
572	Counselling and testing for HIV infection in Rome 1985–1990: Analysis of client characteristics and seroprevalence. European Journal of Epidemiology, 1993, 9, 162-168.	5.7	10
573	Early Abnormalities of the Antibody Response against Mycobacterium tuberculosis in Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1993, 168, 1409-1414.	4.0	16
574	Prevalence of Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus among Dialysis Patients. Nephron, 1993, 64, 636-639.	1.8	32
575	The Risk of Occupational Human Immunodeficiency Virus Infection in Health Care Workers. Archives of Internal Medicine, 1993, 153, 1451.	3.8	266
576	The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. Archives of Internal Medicine, 1993, 153, 1451-1458.	3.8	65

#	Article	IF	Citations
577	The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. Archives of Internal Medicine, 1993, 153, 1451-8.	3.8	56
578	Tuberculosis in HIV-infected subjects in Italy. Aids, 1992, 6, 1007-1014.	2.2	6
579	Needlestick Injury in Hospital Personnel: A Multicenter Survey from Central Italy. Infection Control and Hospital Epidemiology, 1992, 13, 540-544.	1.8	21
580	Zidovudine prophylaxis after accidental exposure to HIV. Aids, 1992, 6, 963-970.	2.2	32
581	Needlestick injury. Lancet, The, 1992, 340, 1166-1167.	13.7	2
582	Prevalence of hepatitis B and C viruses and human immunodeficiency virus infections in women of reproductive age. BJOG: an International Journal of Obstetrics and Gynaecology, 1992, 99, 598-600.	2.3	21
583	Needlestick Injury in Hospital Personnel: A Multicenter Survey From Central Italy. Infection Control and Hospital Epidemiology, 1992, 13, 540-544.	1.8	10
584	Tuberculosis and Human Immunodeficiency Virus Infection in Italy. Chest, 1991, 100, 586.	0.8	4
585	Blind serosurvey of HIV antibodies in newborns in 92 Italian hospitals: a method for monitoring the infection rate in women at time of delivery. Journal of Acquired Immune Deficiency Syndromes, 1991, 4, 402-7.	1.0	10
586	Endotracheal Tube Occlusion, Use of Heat Moisture Exchangers, and Nosocomial Pneumonia. Critical Care Medicine, 1990, 18, 348.	0.9	1
587	Anonymous HIV Testing on Newborns. JAMA - Journal of the American Medical Association, 1990, 263, 36.	7.4	4
588	Risk of HIV Transmission among Health Care Workers: A Multicentre Study. Scandinavian Journal of Infectious Diseases, 1990, 22, 245-246.	1.5	7
589	Needlestick hepatitis C virus seroconversion in a surgeon. Lancet, The, 1990, 336, 1315-1316.	13.7	42
590	Zidovudine in post-exposure prophylaxis of health-care workers. Lancet, The, 1990, 335, 1166-1167.	13.7	28
591	Anonymous HIV testing on newborns. JAMA - Journal of the American Medical Association, 1990, 263, 36b-36.	7.4	3
592	Anonymous HIV testing on newborns. JAMA - Journal of the American Medical Association, 1990, 263, 36.	7.4	1
593	Prevalence of herpes simplex virus type 2 antibodies in selected population groups in Italy. European Journal of Clinical Microbiology and Infectious Diseases, 1988, 7, 54-56.	2.9	13
594	Antiamebic Antibodies in Homosexual Men. New England Journal of Medicine, 1987, 316, 692-692.	27.0	13

#	Article	IF	CITATIONS
595	Recovery of HIV-related Retroviruses From Italian Patients with AIDS or AIDS-related Complex and from Asymptomatic At-Risk Individuals. Annals of the New York Academy of Sciences, 1987, 511, 390-400.	3.8	29
596	CAMPYLOBACTER PYLORI INFECTION IN HOMOSEXUALS. Lancet, The, 1987, 330, 154-155.	13.7	18
597	Cytotoxic necrotizing factor production by hemolytic strains of Escherichia coli causing extraintestinal infections. Journal of Clinical Microbiology, 1987, 25, 146-149.	3.9	134
598	AIDS IN ITALY. Lancet, The, 1984, 324, 642.	13.7	4